根据肿瘤免疫状态分型的糖尿病与结直肠癌风险及生存关系
基于人群的匹配病例对照研究(n=4,724)及结直肠癌病例前瞻性长期随访(n=2,321,中位随访9.5年)显示,2型糖尿病与结直肠癌风险的关联因免疫细胞评分(ICS)而异(异质性P=0.02),风险升高主要见于ICSLow和ICSInt亚型;ICSLow肿瘤患者中,2型糖尿病与更差的结直肠癌特异性生存和DFS相关,而ICSInt和ICSHi亚型中未见此关联。
要点
- 2型糖尿病与结直肠癌风险的关联因免疫细胞评分而异(异质性P=0.02)。
- ICSLow亚型中2型糖尿病与结直肠癌风险升高相关(OR 1.80,95%CI 1.35-2.39)。
- ICSLow肿瘤患者中,2型糖尿病与更差的结直肠癌特异性生存和DFS相关。
核心结论
- 2型糖尿病对低免疫浸润肿瘤的结直肠癌风险和生存影响更显著,提示其影响从肿瘤发生到预后存在连续谱,涉及全身和肿瘤特异性免疫调节。
- 作者认为这些发现突出需要整合代谢和免疫干预的精准预防策略,以减轻2型糖尿病患者的结直肠癌负担。
研究设计与样本
- 基于人群的匹配病例对照研究(n=4,724),并对结直肠癌病例进行前瞻性长期随访(n=2,321;中位随访9.5年)。
- 肿瘤免疫状态采用免疫细胞评分(ICS)评估,基于切除标本中浸润边缘和肿瘤核心的CD3+和CD8+ T细胞密度。
- ICS按标准截断值(25%和70%)分为高(ICSHi)、中(ICSInt)和低(ICSLow)免疫浸润。
- 采用多变量逻辑回归估计结直肠癌风险,采用时间依赖Cox回归评估生存结局;主要终点包括结直肠癌特异性生存和无病生存(DFS)。
主要发现
- 2型糖尿病与结直肠癌风险的关联因ICS而异(异质性P=0.02)。
- 2型糖尿病与结直肠癌风险升高相关(OR 1.39,95%CI 1.17-1.66), particularly for ICSLow(OR 1.80,95%CI 1.35-2.39)和ICSInt亚型(OR 1.42,95%CI 1.17-1.66),但ICSHi亚型无显著关联(OR 1.16,95%CI 0.88-1.52)。
- ICSLow肿瘤的2型糖尿病患者较无2型糖尿病者结直肠癌特异性生存更差(HR 1.99,95%CI 1.30-3.05),DFS也更差(HR 1.53,95%CI 1.05-2.26);ICSInt和ICSHi亚型中未见此关联。
- 2型糖尿病患者无论免疫亚型如何,总生存和非癌症相关生存均较差。
关键数值与推荐
- 2型糖尿病与结直肠癌风险的关联因ICS而异(异质性P=0.02)。
- 2型糖尿病与结直肠癌风险升高相关(OR 1.39,95%CI 1.17-1.66)。
- ICSLow亚型中2型糖尿病与结直肠癌风险升高相关(OR 1.80,95%CI 1.35-2.39)。
- ICSInt亚型中2型糖尿病与结直肠癌风险升高相关(OR 1.42,95%CI 1.17-1.66)。
- ICSHi亚型中2型糖尿病与结直肠癌风险无显著关联(OR 1.16,95%CI 0.88-1.52)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Type 2 diabetes (T2D) has been associated with an increased risk of colorectal cancer (CRC) and poorer survival outcomes. However, the role of tumor immune status in influencing these relationships remains unclear. METHODS: We conducted a population-based matched case-control study (n = 4,724) with prospective long-term follow-up of CRC cases (n = 2,321; median follow-up, 9.5 years). Tumor immune status was assessed using an immune cell score (ICS), derived from CD3+ and CD8+ T-cell densities measured at the invasive margin and tumor core of resected specimens. ICS was stratified into high (ICSHi), intermediate (ICSInt), and low (ICSLow) immune infiltration on the basis of standard cutoffs (25% and 70%). Multivariable logistic regression estimated CRC risk, whereas time-dependent Cox regression evaluated survival outcomes. Primary end points included CRC-specific survival and disease-free survival (DFS). RESULTS: The association between T2D and CRC risk differed significantly by ICS (P for heterogeneity = .02). T2D was associated with an increased risk of CRC (odds ratio [OR], 1.39 [95% CI, 1.17 to 1.66]), particularly for ICSLow (OR, 1.80 [95% CI, 1.35 to 2.39]) and ICSInt subtypes (OR, 1.42 [95% CI, 1.17 to 1.66]), but not for ICSHi CRC subtype (OR, 1.16 [95% CI, 0.88 to 1.52]). Patients with T2D with ICSLow tumors showed poorer CRC-specific survival (hazard ratio [HR], 1.99 [95% CI, 1.30 to 3.05]) and DFS (HR, 1.53 [95% CI, 1.05 to 2.26]) than those without T2D, but not for ICSInt and ICSHi CRC subtypes. Patients with T2D showed inferior overall and non-cancer-related survival regardless of immune subtypes. CONCLUSION: T2D disproportionately affects CRC risk and survival in tumors with low immune infiltration, suggesting a continuum of T2D's impact from tumorigenesis to prognosis, through systemic and tumor-specific immune modulation. These findings highlight the need for precision prevention strategies integrating metabolic and immune-based interventions to mitigate CRC burden in patients with T2D.
引用
- Wankhede D, Halama N, Kloor M, et al. Diabetes and Colorectal Cancer Risk and Survival According to Tumor Immunity Status. J Clin Oncol. 2025. PMID: 40658916. doi:10.1200/JCO-25-00148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。